Search Results
Mar 11, 2026, 02:40 ET 필립스 에브니아-한국외국어대학교 C&T, e스포츠 교육 지원 위한 '에브니아 e스포츠 실습실' 설립
업무 협약식은 한국외국어대학교 부총장 박중찬 교수가 사회를 맡았으며, 글로벌스포츠산업학부 e스포츠 연구센터장 류윤지 교수가 대학 측 대표로 기부 협약식에 공식 서명했다. 필립스 에브니아를 대표해 MMD 아시아태평양 및 대중국 지역 총괄 사장 Yan Lidong 대표가 협약서에 서명하며 "이번 기부 협약은 글로벌 e스포츠 교육 발전을 지원하기 위한 필립스 에브니아의 중요한 발걸음"이라며 "당사의 첨단 디스플레이 기술과 고성능 e스포츠 모니터를 통해 학생들에게 최적의
More news about: Philips Evnia
Jan 20, 2026, 09:00 ET Major Medical Devices Appoints Healthcare Industry Veteran Eric Curtis as Its Chief Executive Officer
am pleased to join MMD as the Company's Chief Executive Officer. I believe medical device innovation in AAA treatment is needed and MMD's next-generation device could become the next standard of care in a condition that impacts 35 million patients worldwide," said Mr. Curtis. "MMD has a team of experts
More news about: Major Medical Devices, Inc.
Jan 09, 2026, 09:00 ET Major Medical Devices Secures Strategic Funding to Advance Novel AAA Repair Device to Market
http://www.majormedicaldevices.com) (MMD), an emerging innovator in vascular intervention technologies with a highly differentiated, potentially quick to market device in a $3 billion market, announces strategic funding partnership with TCA Venture Group (TCA), a leading investment group based in southern California. MMD The partnership
More news about: Major Medical Devices, Inc.
Nov 12, 2025, 15:15 ET OAGi and NIIMBL Announce Release of Biopharmaceutical Manufacturing Ontologies to Advance Interoperability and Analytics
improve usability for ontology specialists and implementation teams," stated Elyse Easson, Director, Commercialization and Digital CMC Value Team, Digital MMD. The biopharmaceutical manufacturing sector has expressed strong support for the availability of this ontology and the advantages
More news about: National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
Oct 16, 2025, 06:05 ET SuperX、NVIDIA GB300搭載のラックマウント型AIプラットフォームを発表、データセンターインフラの次世代標準を提示
48U NVIDIA MGXラック、 2296mm(H) x 600mm(W) x 1200mm(D)
More news about: SuperX AI Technology Ltd
Oct 16, 2025, 06:05 ET SuperX Launches Rack-Scale AI Platform Powered by NVIDIA GB300 Chips, Redefining Data Center Infrastructure
2296mm(H) x 600mm(W) x 1200mm(D)
More news about: SuperX AI Technology Ltd
Oct 03, 2025, 06:35 ET SuperX、最新のXN9160-B300 AIサーバーを発表 -- Blackwell UltraはBlackwellより計算能力が50%向上
8U 447mm(H) x 351mm(W) x 923mm(D)
More news about: SuperX AI Technology Ltd
Oct 03, 2025, 06:35 ET SuperX Launches the Latest XN9160-B300 AI Server, Blackwell Ultra Delivers 50% More Compute Over Blackwell
8U 447mm(H) x 351mm(W) x 923mm(D)
More news about: SuperX AI Technology Ltd
Sep 16, 2025, 07:00 ET ShiraTronics Announces Positive 12-Month Follow-Up Results from RELIEV-CM Pilot Study, Demonstrating Sustained Clinical Benefit with Investigational Implantable Neuromodulation Therapy for Chronic Migraine
Include: 9.6 average reduction in monthly headache days (MHD) from baseline9.6 average reduction in monthly migraine days (MMD) from baselineSustained improvements in migraine-specific quality of life (MSQ) across multiple domainsReduction in rescue medication
More news about: ShiraTronics, Inc.
Sep 11, 2025, 02:27 ET Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
across the open-label period.2 The proportion of participants with a ≥50% or ≥75% MMD reduction from baseline was sustained throughout the trial, with 35.7% of patients achieving a 50% reduction in MMD by week 49-60. A trend towards increasing ≥75% response rate was also observed across the 60-weeks
More news about: H. Lundbeck A/S
Sep 11, 2025, 02:23 ET Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
across the open-label period.2 The proportion of participants with a ≥50% or ≥75% MMD reduction from baseline was sustained throughout the trial, with 35.7% of patients achieving a 50% reduction in MMD by week 49-60. A trend towards increasing ≥75% response rate was also observed across the 60-weeks
More news about: H. Lundbeck A/S
Jul 30, 2025, 06:30 ET SuperX重磅推出全新 SuperX XN9160-B200 AI伺服器，搭載 NVIDIA Blackwell GPU，協助人工智慧創新加速為H100系列的30倍，效能堪比超級電腦！
Dimension 440mm(H) x 448mm(W) x 900mm(D) 市場定位 XN9160-B200面向全球對算力有極高要求的企業與研究機構，尤其適用於以下客戶群體： 大型科技公司
More news about: SuperX AI Technology Ltd
Jul 30, 2025, 06:30 ET SuperXは新製品「SuperX XN9160-B200AI」サーバーを発表
Dimension 440mm(H) x 448mm(W) x 900mm(D) 市場での位置付け XN9160-B200は、計算能力に対する要求が非常に高いグローバル企業や研究機関を対象としており、特に以下の顧客層に適しています：
More news about: SuperX AI Technology Ltd
Jul 30, 2025, 06:30 ET SuperX Unveils the All-New SuperX XN9160-B200 AI Server, Powered by NVIDIA Blackwell GPU -- Accelerating AI Innovation by 30x as Compared to H100 Series with Supercomputer-Class Performance
Dimension 440mm(H) x 448mm(W) x 900mm(D) Market Positioning The XN9160-B200 is designed for global enterprises and research institutions
More news about: SuperX AI Technology Ltd
Jun 21, 2025, 08:56 ET New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine
RESOLUTION trial (n = 608), eptinezumab met the both the primary and secondary endpoints, showing significantly greater monthly migraine day (MMD) reductions through Weeks 1 to 4 with eptinezumab, compared to placebo. Across an average of 21 days, the change from baseline in MMDs was -6.9 with
More news about: H. Lundbeck A/S
Jun 21, 2025, 08:54 ET New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine
RESOLUTION trial (n = 608), eptinezumab met the both the primary and secondary endpoints, showing significantly greater monthly migraine day (MMD) reductions through Weeks 1 to 4 with eptinezumab, compared to placebo. Across an average of 21 days, the change from baseline in MMDs was -6.9 with
More news about: H. Lundbeck A/S
Jun 21, 2025, 08:40 ET New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine
(MMDs), with eptinezumab offering a -7.5 (300 mg) and -7.2 (100 mg) reduction in MMDs from week 1 through to 12, versus -4.8 with placebo (baseline MMD = 17, p<0.0001 for both 300 mg and 100 mg vs placebo).1 Amongst other parameters, patients receiving eptinezumab (300 mg or 100
More news about: H. Lundbeck A/S
Jun 21, 2025, 08:38 ET New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine
(MMDs), with eptinezumab offering a -7.5 (300 mg) and -7.2 (100 mg) reduction in MMDs from week 1 through to 12, versus -4.8 with placebo (baseline MMD = 17, p<0.0001 for both 300 mg and 100 mg vs placebo).1 Amongst other parameters, patients receiving eptinezumab (300 mg or 100
More news about: H. Lundbeck A/S
Jun 18, 2025, 07:15 ET AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
secondary endpoints, including a key measure of clinical efficacy: 64.1% of patients on atogepant achieved a ≥50% reduction in mean monthly migraine days (MMD) during months 4 to 6 of the double-blind treatment period compared to 39.3% of patients on topiramate (p<0.0001).1 "These
More news about: AbbVie